会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • PREPARATION OF A MOLECULAR RECOGNITION ELEMENT
    • 分子识别元素的制备
    • WO2012034946A1
    • 2012-03-22
    • PCT/EP2011/065671
    • 2011-09-09
    • FACHHOCHSCHULE NORDWESTSCHWEIZ, HOCHSCHULE FÜR LIFESCIENCESHAHGALDIAN, PatrickCUMBO, AlessandroCORVINI, Philippe
    • SHAHGALDIAN, PatrickCUMBO, AlessandroCORVINI, Philippe
    • G01N33/543
    • C08G77/18B01J20/268G01N33/54313G01N33/54353G01N2600/00
    • The present invention relates to a method for preparation of a molecular recognition element (1, 11, 111) comprising the steps of binding a template (4) to a surface of a carrier material (3, 30), providing a recognition material to the surface of the carrier material (3, 30), initiating polymerization of the recognition material on the surface of the carrier material (3, 30), stopping the polymerization of the recognition material on the surface of the carrier material (3, 30), and releasing the template (4) from the surface of the carrier material (3, 30) and the polymerized recognition material (6, 60). The method is characterized in that an aim size of individual imprints (10, 100, 120) is predefined, and the polymerization of the recognition material on the surface of the carrier material (3, 30) is stopped when a size of individual imprints (10, 100, 120) of the polymerized recognition material (6, 60) essentially equals the predefined aim size. This method is readily applicable for preparation of a molecular recognition element al (1, 11, 111) useful as a drug, catalyst, competitive affinity ligand inhibitor, competitor, agonist, antagonist or diagnostic agent.
    • 本发明涉及一种用于制备分子识别元件(1,11,111)的方法,包括以下步骤:将模板(4)结合到载体材料(3,30)的表面,从而提供识别材料 在载体材料(3,30)的表面上引发识别材料在载体材料(3,30)的表面上的聚合,停止识别材料在载体材料(3,30)的表面上的聚合, 以及从载体材料(3,30)的表面和聚合的识别材料(6,60)释放模板(4)。 该方法的特征在于,预定了单个印记(10,100,120)的目标尺寸,并且当个体印记的尺寸(...)时,停止载体材料(3,30)表面上识别材料的聚合 聚合识别材料(6,60)10,100,120)基本上等于预定义的目标尺寸。 该方法可用于制备可用作药物,催化剂,竞争性亲和配体抑制剂,竞争剂,激动剂,拮抗剂或诊断剂的分子识别元件al(1,11,111)。
    • 9. 发明申请
    • IMPROVED PURIFICATION OF MULTI-SPECIFIC RECEPTORS
    • 改善多特异性受体的纯化
    • WO2011033021A2
    • 2011-03-24
    • PCT/EP2010/063614
    • 2010-09-16
    • MIPSALUS APSKROGH, Nicolas, OttoGREGORIUS, Klaus
    • KROGH, Nicolas, OttoGREGORIUS, Klaus
    • B01D15/38
    • A61K31/74B01D15/1807B01D15/3804B01J20/26B01J20/268
    • Disclosed is a method for preparing a composition enriched for receptors (typically molecular impringet polymers, MIPs) that bind an agent, where said receptors each specifically bind at least two discrete sites on said agent, by subjecting a sample of receptors to a first step of affinity purification with the agent where one binding site on the agent is non-accessible for binding to the receptors and subsequently subjecting the purified receptors to at least one further step of affinity purification with the agent where a second binding site on the agent is non-accessible. Also disclosed is a method for treatment, amelioration or prophylaxis of a disease selected from the group consisting of phenylketonuria (PKU, Følling's disease), hyperphenylalaninemia (HPA), alcaptonuria (black urine disease), tyrosinemia, hypertyrosinemia, myasthenia gravis, histidinemia, urocanic aciduria, maple syrup urine disease (MSUD), isovaleric acidemia (isovaleryl-CoA dehydrogenase deficiency), homocystinuria, propionic acidemia, methylmalonic acidemia, and glutaric aciduria Type 1 (GA-I), galactosemia, comprising administering to the gastrointestinal tract of a patient in need thereof an effective amount of a composition of molecular imprinted polymers (MIPs), said composition being capable of binding a symptom provoking agent of said disease.
    • 公开了一种制备富集结合试剂的受体(通常是分子侵入物聚合物,MIP)的组合物的方法,其中所述受体通过使受体样品经受第一步的第一步,每个特异性结合所述试剂上的至少两个离散位点 与试剂亲和纯化,其中试剂上的一个结合位点不能与受体结合,随后使纯化的受体与试剂上的第二结合位点不相容的至少一个亲和纯化的另外步骤进行, 无障碍。 还公开了治疗,改善或预防选自苯丙酮尿症(PKU,Følling氏病),高苯丙氨酸血症(HPA),尿磷酸尿症(黑尿病),酪氨酸血症,高铁血症,重症肌无力,组氨酸血症,尿路感染 尿酸,枫糖尿病(MSUD),异戊酸 - 乙酰脱氢酶缺乏症,同型半胱氨酸尿,丙酸血症,甲基丙二酸血症和戊二酸1型糖尿病(GA-I),半乳糖血症,包括给予患者胃肠道 在需要时,有效量的分子印迹聚合物(MIP)的组合物,所述组合物能够结合所述疾病的症状发作剂。